Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
fda
genentech
2
×
life sciences
national blog main
national top stories
roche
2
×
billy dunn
biogen
boston
boston blog main
boston top stories
cancer
cancer immunotherapy
center for medicare and medicaid services
clinical trials
companion diagnostic
daniel o'day
deals
drug prices
drug pricing
europe top stories
evrysdi
foundation medicine
foundationone cdx
foundationone heme
gene therapy
ionis pharmaceuticals
national
new york blog main
new york top stories
novartis
nusinersen
osimertinib
risdiplam
rna drugs
rucaparib (rubraca)
san francisco blog main
san francisco top stories
spinal muscular atrophy
What
medicine
2
×
roche
2
×
acquire
agreed
approved
atrophy
big
billion
broad
confidence
daily
didn’t
drug
evrysdi
fda
foundation
friday
gain
genentech
green
home
intended
lights
liquid
momentum
morning
muscular
new
oral
panels
patients
pay
pays
picked
profiling
recently
redux
remaining
rest
risdiplam
Language
unset
Current search:
roche
×
genentech
×
medicine
×
roche
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine